Last reviewed · How we verify
rhprouk
rhprouk is a Small molecule drug developed by Suzhou RxD Biopharmaceutical Co., Ltd. It is currently in Phase 3 development. Also known as: Controlled.
Rhprouk is being studied in a Phase III clinical trial for the treatment of STEMI (ST Elevated Myocardial Infarction) patients in China. The trial, NCT02367976, is being conducted by Suzhou RxD Biopharmaceutical Co., Ltd.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | rhprouk |
|---|---|
| Also known as | Controlled |
| Sponsor | Suzhou RxD Biopharmaceutical Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhprouk CI brief — competitive landscape report
- rhprouk updates RSS · CI watch RSS
- Suzhou RxD Biopharmaceutical Co., Ltd portfolio CI
Frequently asked questions about rhprouk
What is rhprouk?
Who makes rhprouk?
Is rhprouk also known as anything else?
What development phase is rhprouk in?
Related
- Manufacturer: Suzhou RxD Biopharmaceutical Co., Ltd — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Controlled
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing